Estonia's leading university hospital contributing clinical cohorts, patient data, and digital health expertise to European research on chronic and immune-mediated diseases.
Tartu University Hospital is Estonia's largest hospital and a leading clinical research centre in the Baltic region. They contribute clinical expertise, patient cohorts, and real-world health data to European research consortia studying chronic and immune-mediated diseases, stroke prevention, and digital health solutions. Their work bridges clinical medicine with data-driven approaches — from birth cohort studies and exposome research to federated learning for secure health data management across borders.
HEDIMED studies exposomic determinants of immune diseases (type 1 diabetes, celiac disease, allergy, asthma) using birth cohorts, while RE-SAMPLE addresses COPD and multi-morbidity management.
PRECIOUS ran a randomised clinical trial on preventing complications and improving functional outcomes in elderly stroke patients.
RE-SAMPLE focuses on GDPR-compliant federated learning, privacy-preserving data sharing, and AI-driven clinical decision support for chronic disease.
SZ_TEST investigated early molecular diagnostics and biomarkers for schizophrenia through a MSCA-RISE mobility project.
Their early H2020 work (2015–2017) centred on traditional clinical research — a stroke prevention trial in elderly patients and molecular biomarker discovery for schizophrenia. From 2020 onward, the focus shifted decisively toward data-intensive, multi-disease research: large-scale exposome studies linking environmental factors to immune diseases, and digital health platforms using federated learning and AI for chronic disease management. The trajectory shows a hospital moving from single-disease clinical trials toward complex, data-rich population health studies.
Tartu University Hospital is building capacity in privacy-preserving health data analytics and AI-driven clinical decision support — expect them to seek partners in federated learning, multi-morbidity management, and digital health infrastructure.
Exclusively a participant — they have never coordinated an H2020 project, which is typical for a clinical partner providing patient data, cohorts, and clinical validation rather than leading research design. With 60 unique partners across 19 countries, they integrate into large, diverse consortia rather than small focused teams. This makes them an accessible and experienced partner who understands multi-site clinical collaboration without requiring a leadership role.
They have collaborated with 60 distinct partners across 19 countries, indicating broad European reach for a mid-sized Estonian institution. Their network spans clinical centres, universities, and digital health organisations across the EU.
As Estonia's primary university hospital, they offer something rare in EU consortia: access to well-organized Nordic-style health registries and patient data in a country known for advanced digital governance (e-Estonia). They combine clinical trial capacity with a digitally mature healthcare environment, making them an ideal partner for projects that need real-world patient data under strong data protection frameworks. For consortium builders, they fill the dual role of clinical site and digital health data provider from an underrepresented EU-13 country — valuable for geographic balance requirements.
